395 related articles for article (PubMed ID: 27589831)
1. Cell-permeable iron inhibits vascular endothelial growth factor receptor-2 signaling and tumor angiogenesis.
Kir D; Saluja M; Modi S; Venkatachalam A; Schnettler E; Roy S; Ramakrishnan S
Oncotarget; 2016 Oct; 7(40):65348-65363. PubMed ID: 27589831
[TBL] [Abstract][Full Text] [Related]
2. Magnolol suppresses hypoxia-induced angiogenesis via inhibition of HIF-1α/VEGF signaling pathway in human bladder cancer cells.
Chen MC; Lee CF; Huang WH; Chou TC
Biochem Pharmacol; 2013 May; 85(9):1278-87. PubMed ID: 23416116
[TBL] [Abstract][Full Text] [Related]
3. Tanshinone IIA inhibits β-catenin/VEGF-mediated angiogenesis by targeting TGF-β1 in normoxic and HIF-1α in hypoxic microenvironments in human colorectal cancer.
Sui H; Zhao J; Zhou L; Wen H; Deng W; Li C; Ji Q; Liu X; Feng Y; Chai N; Zhang Q; Cai J; Li Q
Cancer Lett; 2017 Sep; 403():86-97. PubMed ID: 28602978
[TBL] [Abstract][Full Text] [Related]
4. Multiple receptor tyrosine kinases regulate HIF-1alpha and HIF-2alpha in normoxia and hypoxia in neuroblastoma: implications for antiangiogenic mechanisms of multikinase inhibitors.
Nilsson MB; Zage PE; Zeng L; Xu L; Cascone T; Wu HK; Saigal B; Zweidler-McKay PA; Heymach JV
Oncogene; 2010 May; 29(20):2938-49. PubMed ID: 20208561
[TBL] [Abstract][Full Text] [Related]
5. Fasudil-induced hypoxia-inducible factor-1alpha degradation disrupts a hypoxia-driven vascular endothelial growth factor autocrine mechanism in endothelial cells.
Takata K; Morishige K; Takahashi T; Hashimoto K; Tsutsumi S; Yin L; Ohta T; Kawagoe J; Takahashi K; Kurachi H
Mol Cancer Ther; 2008 Jun; 7(6):1551-61. PubMed ID: 18566226
[TBL] [Abstract][Full Text] [Related]
6. GABARBP down-regulates HIF-1α expression through the VEGFR-2 and PI3K/mTOR/4E-BP1 pathways.
Park SH; Kim BR; Lee JH; Park ST; Lee SH; Dong SM; Rho SB
Cell Signal; 2014 Jul; 26(7):1506-13. PubMed ID: 24686084
[TBL] [Abstract][Full Text] [Related]
7. Hypoxia-inducible factors promote alveolar development and regeneration.
Vadivel A; Alphonse RS; Etches N; van Haaften T; Collins JJ; O'Reilly M; Eaton F; Thébaud B
Am J Respir Cell Mol Biol; 2014 Jan; 50(1):96-105. PubMed ID: 23962064
[TBL] [Abstract][Full Text] [Related]
8. Loss of miR-145-5p Causes Ceruloplasmin Interference with PHD-Iron Axis and HIF-2α Stabilization in Lung Adenocarcinoma-Mediated Angiogenesis.
Tsai YM; Wu KL; Chang YY; Chang WA; Huang YC; Jian SF; Tsai PH; Lin YS; Chong IW; Hung JY; Hsu YL
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32708433
[TBL] [Abstract][Full Text] [Related]
9. Sunitinib but not VEGF blockade inhibits cancer stem cell endothelial differentiation.
Brossa A; Grange C; Mancuso L; Annaratone L; Satolli MA; Mazzone M; Camussi G; Bussolati B
Oncotarget; 2015 May; 6(13):11295-309. PubMed ID: 25948774
[TBL] [Abstract][Full Text] [Related]
10. Antiangiogenic Potential of Microbial Metabolite Elaiophylin for Targeting Tumor Angiogenesis.
Lim HN; Jang JP; Han JM; Jang JH; Ahn JS; Jung HJ
Molecules; 2018 Mar; 23(3):. PubMed ID: 29498688
[TBL] [Abstract][Full Text] [Related]
11. Hypoxia-inducible factor-2α regulates GM-CSF-derived soluble vascular endothelial growth factor receptor 1 production from macrophages and inhibits tumor growth and angiogenesis.
Roda JM; Sumner LA; Evans R; Phillips GS; Marsh CB; Eubank TD
J Immunol; 2011 Aug; 187(4):1970-6. PubMed ID: 21765015
[TBL] [Abstract][Full Text] [Related]
12. A hypoxia-driven vascular endothelial growth factor/Flt1 autocrine loop interacts with hypoxia-inducible factor-1alpha through mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2 pathway in neuroblastoma.
Das B; Yeger H; Tsuchida R; Torkin R; Gee MF; Thorner PS; Shibuya M; Malkin D; Baruchel S
Cancer Res; 2005 Aug; 65(16):7267-75. PubMed ID: 16103078
[TBL] [Abstract][Full Text] [Related]
13. Suppression of VEGF expression through interruption of the HIF‑1α and Akt signaling cascade modulates the anti‑angiogenic activity of DAPK in ovarian carcinoma cells.
Park ST; Kim BR; Park SH; Lee JH; Lee EJ; Lee SH; Rho SB
Oncol Rep; 2014 Feb; 31(2):1021-9. PubMed ID: 24337450
[TBL] [Abstract][Full Text] [Related]
14. Aspirin Affects Tumor Angiogenesis and Sensitizes Human Glioblastoma Endothelial Cells to Temozolomide, Bevacizumab, and Sunitinib, Impairing Vascular Endothelial Growth Factor-Related Signaling.
Navone SE; Guarnaccia L; Cordiglieri C; Crisà FM; Caroli M; Locatelli M; Schisano L; Rampini P; Miozzo M; La Verde N; Riboni L; Campanella R; Marfia G
World Neurosurg; 2018 Dec; 120():e380-e391. PubMed ID: 30144594
[TBL] [Abstract][Full Text] [Related]
15. Ellagic acid inhibits VEGF/VEGFR2, PI3K/Akt and MAPK signaling cascades in the hamster cheek pouch carcinogenesis model.
Kowshik J; Giri H; Kishore TK; Kesavan R; Vankudavath RN; Reddy GB; Dixit M; Nagini S
Anticancer Agents Med Chem; 2014; 14(9):1249-60. PubMed ID: 25060902
[TBL] [Abstract][Full Text] [Related]
16. The antihypertension drug doxazosin inhibits tumor growth and angiogenesis by decreasing VEGFR-2/Akt/mTOR signaling and VEGF and HIF-1α expression.
Park MS; Kim BR; Dong SM; Lee SH; Kim DY; Rho SB
Oncotarget; 2014 Jul; 5(13):4935-44. PubMed ID: 24952732
[TBL] [Abstract][Full Text] [Related]
17. DDA suppresses angiogenesis and tumor growth of colorectal cancer in vivo through decreasing VEGFR2 signaling.
Huang SW; Lien JC; Kuo SC; Huang TF
Oncotarget; 2016 Sep; 7(39):63124-63137. PubMed ID: 27517319
[TBL] [Abstract][Full Text] [Related]
18. Dietary compound isoliquiritigenin inhibits breast cancer neoangiogenesis via VEGF/VEGFR-2 signaling pathway.
Wang Z; Wang N; Han S; Wang D; Mo S; Yu L; Huang H; Tsui K; Shen J; Chen J
PLoS One; 2013; 8(7):e68566. PubMed ID: 23861918
[TBL] [Abstract][Full Text] [Related]
19. Myocardial hypertrophy overrides the angiogenic response to hypoxia.
Choi YH; Cowan DB; Nathan M; Poutias D; Stamm C; del Nido PJ; McGowan FX
PLoS One; 2008; 3(12):e4042. PubMed ID: 19112498
[TBL] [Abstract][Full Text] [Related]
20. sMEK1 inhibits endothelial cell proliferation by attenuating VEGFR-2-dependent-Akt/eNOS/HIF-1α signaling pathways.
Kim BR; Seo SH; Park MS; Lee SH; Kwon Y; Rho SB
Oncotarget; 2015 Oct; 6(31):31830-43. PubMed ID: 26378810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
